Surefire Medical, Inc., a Westminster, Colo.-based commercial stage company developing a new class of direct-to-tumor delivery systems employed in minimally invasive interventional procedures, closed a $15M Series C financing.
The round was led by Tullis Health Investors, with participation from KMG Capital Partners, Partisan Management Group, MCG Partners, High Country Ventures and angel investors.
The company intends to use the funds for the global launch of its new device Surefire Precision.
Founded in 2009 and led by James Chomas, President and CEO, Surefire Medical develops infusion systems for the Interventional Radiology and the Interventional Oncology markets.
Surefire Precision is a device specifically designed to meet the clinical need for targeted delivery systems in the treatment of primary liver cancer (HCC).
The company’s products have received regulatory approval in the U.S., Europe, Canada, Australia, New Zealand, Taiwan, Mexico and Brazil.